Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Daunorubicin hydrochloride - >90%, high purity , DNA inhibitor, CAS No.23541-50-6, DNA inhibitor

3 Citations
  • ≥90%
Item Number
D122335
Grouped product items
SKUSizeAvailabilityPrice Qty
D122335-10mg
10mg
In stock
$9.90
D122335-50mg
50mg
In stock
$19.90
D122335-250mg
250mg
In stock
$49.90
D122335-1g
1g
In stock
$139.90
Add to Wish List Compare
Bulk Order  SDS  DATASHEET

Anthracycline antibiotic. DNA and RNA synthesis inhibitor.

View related series
Apoptosis Chemical Biology Tetracyclines

Basic Description

SynonymsDAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HCL | Daunomycin hydrochloride | Cerubidine | Daunomycin chlorohydrate | RP-13057 Hydrochloride | Daunomycin, hydrochloride | Daunoblastina | RP 13057 hydrochloride | Rubidomycin hydrochloride | Daunomycin HCL | O
Specifications & Purity≥90%
Biochemical and Physiological MechanismsDaunorubicin hydrochloride is a DNA intercalating anthracylcine natural product isolated from Streptomyces peucetius. Upon intercalation, Daunorubicin forms stable complexes with the DNA backbone, inhibiting normal functioning of the double helix and the
Storage TempStore at -20°C,Argon charged
Shipped InIce chest + Ice pads
Action TypeINHIBITOR
Mechanism of actionDNA inhibitor
NoteWherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.
A DNA intercalator which may suppress acute leukemia proliferation

Associated Targets(Human)

S100A4 Tchem Protein S100-A4 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
VDR Tclin Vitamin D receptor (26531 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TSHR Tclin Thyroid stimulating hormone receptor (29986 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PPARG Tclin Peroxisome proliferator-activated receptor gamma (15191 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TNF Tclin TNF-alpha (1897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
THRB Tclin Thyroid hormone receptor beta-1 (7926 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RXRA Tclin Retinoid X receptor alpha (3637 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CXCL8 Tchem Interleukin-8 (642 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
POLB Tchem DNA polymerase beta (23632 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AHR Tclin Aryl hydrocarbon receptor (1071 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PLK1 Tchem Serine/threonine-protein kinase PLK1 (28605 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NFKB1 Tclin Nuclear factor NF-kappa-B p105 subunit (1459 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GLP1R Tclin Glucagon-like peptide 1 receptor (111429 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PIN1 Tchem Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 (36611 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FPR1 Tchem Formyl peptide receptor 1 (1372 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CYP3A4 Tclin Cytochrome P450 3A4 (53859 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TP53 Tchem Cellular tumor antigen p53 (48468 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A204 (242 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
A498 (42825 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CAPAN-1 (772 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
EVSA-T (142 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HL-60 (67320 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HT-29 (80576 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
K562 (73714 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MCF7 (126967 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MOLT-4 (49676 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NHDF (1164 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
OVCAR-3 (48710 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PC-3 (62116 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SK-MEL-28 (48833 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
T-24 (2342 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
UCLA P-3 (10 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HCT-116 (91556 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HEK293 (82097 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HMEC (560 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
WiDr (1835 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HepG2 (196354 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IGROV-1 (47897 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
IGR-37 cell line (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
LNCaP (8286 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Lymphoblastoid cell (5959 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
M19-MEL (15326 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HeLa (62764 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MDA-MB-231 (73002 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SW-620 (52400 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FEN1 Tchem Flap endonuclease 1 (12055 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HIF1A Tchem Hypoxia-inducible factor 1 alpha (6027 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ppard Peroxisome proliferator-activated receptor delta (358 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Salmonella typhimurium (15756 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Plasmodium falciparum (966862 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CHO (4503 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
L1210 (27553 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
P388 (20296 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
M109 (194 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Calf thymus DNA (4845 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Salmon testes DNA (254 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
lef Anthrax lethal factor (7585 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Npsr1 Neuropeptide S receptor (260 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Luciferin 4-monooxygenase (66902 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BCHE Cholinesterase (8742 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapt Microtubule-associated protein tau (6 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Nfe2l2 Nuclear factor erythroid 2-related factor 2 (214 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rorc Nuclear receptor ROR-gamma (89407 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
fba Putative fructose-1,6-bisphosphate aldolase (15559 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Impa1 Inositol monophosphatase 1 (16203 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ffp 4'-phosphopantetheinyl transferase ffp (24982 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FTL Ferritin light chain (43324 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
NS1 Nonstructural protein 1 (33327 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ORF 73 (309 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rpoB Bacterial DNA-directed RNA polymerase (88 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

Pubchem Sid488183611
Pubchem Sid Urlhttps://pubchem.ncbi.nlm.nih.gov/substance/488183611
IUPAC Name (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
INCHI InChI=1S/C27H29NO10.ClH/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;1H/t10-,14-,16-,17-,22+,27-;/m0./s1
InChi Key GUGHGUXZJWAIAS-QQYBVWGSSA-N
Canonical SMILES Cl.COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O
Isomeric SMILES C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)C)O)N)O.Cl
WGK Germany 3
RTECS HB7878000
Alternate CAS 20830-81-3
PubChem CID 62770
UN Number 2811
Packing Group I
Molecular Weight 563.98
Beilstein 4229221

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

12 results found

Lot NumberCertificate TypeDateItem
F2428225Certificate of AnalysisJun 03, 2024 D122335
F2428226Certificate of AnalysisJun 03, 2024 D122335
F2428227Certificate of AnalysisJun 03, 2024 D122335
F2428228Certificate of AnalysisJun 03, 2024 D122335
C2308992Certificate of AnalysisDec 17, 2022 D122335
C2308993Certificate of AnalysisDec 17, 2022 D122335
C2308994Certificate of AnalysisDec 17, 2022 D122335
C2308995Certificate of AnalysisDec 17, 2022 D122335
C2308996Certificate of AnalysisDec 17, 2022 D122335
C2308997Certificate of AnalysisDec 17, 2022 D122335
C2308998Certificate of AnalysisDec 17, 2022 D122335
K2210228Certificate of AnalysisSep 06, 2021 D122335

Show more⌵

Chemical and Physical Properties

SolubilitySoluble in water (≥113), methanol, ethanol (≥10), and DMSO (≥72 mg/mL).
SensitivityMoisture & heat sensitive.light sensitive
Specific Rotation[α]260°
Melt Point(°C)167 °C

Safety and Hazards(GHS)

Pictogram(s) GHS06,   GHS08,   GHS07
Signal Danger
Hazard Statements

H301:Toxic if swallowed

H341:Suspected of causing genetic defects

H351:Suspected of causing cancer

H302:Harmful if swallowed

H334:May cause allergy or asthma symptoms or breathing difficulties if inhaled

H360:May damage fertility or the unborn child

Precautionary Statements

P261:Avoid breathing dust/fume/gas/mist/vapors/spray.

P280:Wear protective gloves/protective clothing/eye protection/face protection.

P321:Specific treatment (see ... on this label).

P405:Store locked up.

P501:Dispose of contents/container to ...

P264:Wash hands [and …] thoroughly after handling.

P284:[In case of inadequate ventilation] Wear respiratory protection.

P281:Use personal protective equipment as required.

P270:Do not eat, drink or smoke when using this product.

P304+P340:IF INHALED: Remove person to fresh air and keep comfortable for breathing.

P330:Rinse mouth.

P203:Obtain, read and follow all safety instructions before use.

P301+P316:IF SWALLOWED: Get emergency medical help immediately.

P301+P317:IF SWALLOWED: Get medical help.

P318:if exposed or concerned, get medical advice.

P342+P316:If experiencing respiratory symptoms: Get emergence medical help immediately.

WGK Germany 3
RTECS HB7878000
Class 6.1
Merck Index 2832

Related Documents

 SDS

 Specification Sheet

Alternative Products

  1. Daunorubicin (RP 13057) HCl - 10mM in DMSO, used for , CAS No. 23541-50-6(DMSO), by Aladdin Scientific
    Daunorubicin (RP 13057) HCl
    • 10mM in DMSO

    Starting at $54.90

  2. 8-Desacetyl-8-carboxy Daunorubicin Hydrochloride Hydrate
    8-Desacetyl-8-carboxy Daunorubicin Hydrochloride Hydrate
    • ≥95%

    Starting at $148.90

  3. Ala-Leu-Ala-Leu Daunorubicin hydrochloride
    Ala-Leu-Ala-Leu Daunorubicin hydrochloride

    Starting at $10,450.90

  4. 4′-epi-Daunorubicin Hydrochloride
    4′-epi-Daunorubicin Hydrochloride

    Starting at $760.90

FAQs and Articles

FAQ
Antibody-drug Conjugates: A Comprehensive Guide
Categories: Technical articles
Tags:
Biomedical materials tumor cell Antibody drug conjugates

Citations of This Product

How to Cite Aladdin Scientific Products?
1. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo.  (2023)  Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels.  JOURNAL OF CONTROLLED RELEASE,  360  (433).  [PMID:37422124]
2. Bo Fu, Can Tao, Nian Chen, Jie-Rou Lin, Ping Zhao.  (2021)  ZnO QD covalently coated, GSH/pH dual-responsive drug delivery system for chemotherapeutic/ionic synergistic therapy.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,  66  (102908).  [PMID:]
3. Zhifeng Xu, Peihong Deng, Junhua Li, Li Xu, Siping Tang.  (2017)  Molecularly imprinted fluorescent probe based on FRET for selective and sensitive detection of doxorubicin.  Materials Science and Engineering B-Advanced Functional Solid-State Materials,  218  (31).  [PMID:]

References

1. Pengcheng Shi,Jie Zha,Xutao Guo,Feili Chen,Zhiping Fan,Fen Huang,Fanyi Meng,Xiaoli Liu,Ru Feng,Bing Xu.  (2012-12-21)  Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression..  Pharmacogenomics,  14  ((1)): (17-23).  [PMID:23252945]
2. Tereza Hartmanová,Vojtěch Tambor,Juraj Lenčo,Claudia A Staab-Weijnitz,Edmund Maser,Vladimír Wsól.  (2013-01-09)  S-nitrosoglutathione covalently modifies cysteine residues of human carbonyl reductase 1 and affects its activity..  Chemico-biological interactions,  202  ((1-3)): (136-145).  [PMID:23295225]
3. Mingjuan Liu,Ji Liu,Lihui Liu,Li Yu,Bing Shi,Liping Ye,Yongqing Zhang,Hu Chen.  (2013-01-09)  A case report of acute myeloid leukemia after liver transplantation..  Acta haematologica,  129  ((4)): (225-228).  [PMID:23295767]
4. Pranjal Chandra,Hui-Bog Noh,Yoon-Bo Shim.  (2013-01-09)  Cancer cell detection based on the interaction between an anticancer drug and cell membrane components..  Chemical communications (Cambridge, England),  49  ((19)): (1900-1902).  [PMID:23296144]
5. Utz Krug,Anja Koschmieder,Daniela Schwammbach,Joachim Gerss,Nicola Tidow,Björn Steffen,Gesine Bug,Christian H Brandts,Markus Schaich,Christoph Röllig,Christian Thiede,Richard Noppeney,Matthias Stelljes,Thomas Büchner,Steffen Koschmieder,Ulrich Dührsen,Hubert Serve,Gerhard Ehninger,Wolfgang E Berdel,Carsten Müller-Tidow.  (2013-01-10)  Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study..  PloS one,  7  ((12)): (e52695-e52695).  [PMID:23300745]
6. Gertjan J L Kaspers,Martin Zimmermann,Dirk Reinhardt,Brenda E S Gibson,Rienk Y J Tamminga,Olga Aleinikova,Hortensia Armendariz,Michael Dworzak,Shau-Yin Ha,Henrik Hasle,Liisa Hovi,Alexei Maschan,Yves Bertrand,Guy G Leverger,Bassem I Razzouk,Carmelo Rizzari,Petr Smisek,Owen Smith,Batia Stark,Ursula Creutzig.  (2013-01-16)  Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  31  ((5)): (599-607).  [PMID:23319696]
7. S Park,N Chapuis,F Saint Marcoux,C Recher,T Prebet,P Chevallier,J-Y Cahn,T Leguay,P Bories,F Witz,T Lamy,P Mayeux,C Lacombe,C Demur,J Tamburini,A Merlat,R Delepine,N Vey,F Dreyfus,M C Béné,N Ifrah,D Bouscary.  (2013-01-17)  A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse..  Leukemia,  27  ((7)): (1479-1486).  [PMID:23321953]
8. Rocky Pramanik,Xia Sheng,Brian Ichihara,Nora Heisterkamp,Steven D Mittelman.  (2013-01-22)  Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy..  Leukemia research,  37  ((5)): (503-509).  [PMID:23332453]
9. Mona Hassanein,Eshetu G Atenafu,Andre C Schuh,Karen W L Yee,Mark D Minden,Aaron D Schimmer,Vikas Gupta,Joseph M Brandwein.  (2013-01-30)  High-dose cytarabine-based consolidation shows superior results for older AML patients with intermediate risk cytogenetics in first complete remission..  Leukemia research,  37  ((5)): (556-560).  [PMID:23357460]
10. Sarah Bertoli,Emilie Bérard,Françoise Huguet,Anne Huynh,Suzanne Tavitian,François Vergez,Sophie Dobbelstein,Nicole Dastugue,Véronique Mansat-De Mas,Eric Delabesse,Eliane Duchayne,Cécile Demur,Audrey Sarry,Valérie Lauwers-Cances,Guy Laurent,Michel Attal,Christian Récher.  (2013-02-01)  Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia..  Blood,  121  ((14)): (2618-2626).  [PMID:23365464]
11. Oliver Teuffel,Kurt Leibundgut,Thomas Lehrnbecher,Todd A Alonzo,Joseph Beyene,Lillian Sung.  (2013-02-13)  Anthracyclines during induction therapy in acute myeloid leukaemia: a systematic review and meta-analysis..  British journal of haematology,  161  ((2)): (192-203).  [PMID:23398482]
12. G M Marshall,L Dalla Pozza,R Sutton,A Ng,H A de Groot-Kruseman,V H van der Velden,N C Venn,H van den Berg,E S J M de Bont,R Maarten Egeler,P M Hoogerbrugge,G J L Kaspers,M B Bierings,E van der Schoot,J van Dongen,T Law,S Cross,H Mueller,V de Haas,M Haber,T Révész,F Alvaro,R Suppiah,M D Norris,R Pieters.  (2013-02-15)  High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation..  Leukemia,  27  ((7)): (1497-1503).  [PMID:23407458]
13. Marko Kavcic,Brian T Fisher,Yimei Li,Alix E Seif,Kari Torp,Dana M Walker,Yuan-Shung Huang,Grace E Lee,Sarah K Tasian,Marijana Vujkovic,Rochelle Bagatell,Richard Aplenc.  (2013-02-26)  Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States..  Cancer,  119  ((10)): (1916-1923).  [PMID:23436301]
14. Richard M Stone.  (2013-02-27)  Acute myeloid leukemia in first remission: to choose transplantation or not?.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology,  31  ((10)): (1262-1266).  [PMID:23439752]
15. Nobuhiro Hiramoto,Yukio Kobayashi,Junko Nomoto,Dai Maruyama,Takashi Watanabe,Naobumi Tochigi,Koh Furuta,Ken Takeda,Hirokazu Chuman,Shigeki Yagyu,Hajime Hosoi,Kensei Tobinai.  (2013-03-12)  Ewing sarcoma arising after treatment of diffuse large B-cell lymphoma..  Japanese journal of clinical oncology,  43  ((4)): (417-421).  [PMID:23475435]
16. Lili Xiang,Man Li,Yan Liu,Jiangnong Cen,Zixing Chen,Xiao Zhen,Xiaobao Xie,Xiangshan Cao,Weiying Gu.  (2013-03-22)  The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia..  Annals of hematology,  92  ((8)): (1063-1069).  [PMID:23515710]
17. Benjamin Doughty,Yi Rao,Samuel W Kazer,Sheldon J J Kwok,Nicholas J Turro,Kenneth B Eisenthal.  (2013-03-27)  Probing the relative orientation of molecules bound to DNA through controlled interference using second-harmonic generation..  Proceedings of the National Academy of Sciences of the United States of America,  110  ((15)): (5756-5758).  [PMID:23530200]
18. Weiwei Jiang,Bin Li,Xinchuan Zheng,Xin Liu,Xichun Pan,Rongxin Qing,Yanyan Cen,Jiang Zheng,Hong Zhou.  (2013-04-04)  Artesunate has its enhancement on antibacterial activity of β-lactams via increasing the antibiotic accumulation within methicillin-resistant Staphylococcus aureus (MRSA)..  The Journal of antibiotics,  66  ((6)): (339-345).  [PMID:23549351]
19. Sang Min Lee,Won Sik Lee,Ho Jin Shin,Je-Jung Lee,Sang Kyun Sohn,Joon Ho Moon,Hyeon Seok Eom,Jong Ho Won,Kyoo-Hyung Lee,Je-Hwan Lee,Dae-Young Kim,Sung-Soo Yoon,Inho Kim,Chul Won Jung,Seok Jin Kim,Hawk Kim,Jae Hoon Lee,Hun-Mo Ryoo,Gyeong-Won Lee,Sung-Hyun Kim,Yeung-Chul Mun,Min Kyoung Kim,Young Don Joo.  (2013-04-06)  Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia..  Annals of hematology,  92  ((8)): (1101-1110).  [PMID:23558905]
20. Ursula Creutzig,Martin Zimmermann,Jean-Pierre Bourquin,Michael N Dworzak,Gudrun Fleischhack,Norbert Graf,Thomas Klingebiel,Bernhard Kremens,Thomas Lehrnbecher,Christine von Neuhoff,Jörg Ritter,Annette Sander,André Schrauder,Arend von Stackelberg,Jan Starý,Dirk Reinhardt.  (2013-05-25)  Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004..  Blood,  122  ((1)): (37-43).  [PMID:23704089]
21. Abhi Das,Gopinatha Suresh Kumar.  (2013-06-19)  Binding of the plant alkaloid aristololactam-β-d-glucoside and antitumor antibiotic daunomycin to single stranded polyribonucleotides..  Biochimica et biophysica acta,  1830  ((10)): (4708-4718).  [PMID:23769768]
22. Eduard Jirkovský,Olga Lenčová-Popelová,Miloš Hroch,Michaela Adamcová,Yvona Mazurová,Jaroslava Vávrová,Stanislav Mičuda,Tomáš Šimůnek,Vladimír Geršl,Martin Štěrba.  (2013-07-09)  Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits..  Toxicology,  311  ((3)): (191-204).  [PMID:23831762]
23. Cedric Dos Santos,Tinisha McDonald,Yin Wei Ho,Hongjun Liu,Allen Lin,Stephen J Forman,Ya-Huei Kuo,Ravi Bhatia.  (2013-07-31)  The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents..  Blood,  122  ((11)): (1900-1913).  [PMID:23896410]
24. S Singh-Rambiritch,N H Wood.  (2013-08-21)  Post-chemotherapeutic resolution of acute myeloid leukaemia-induced gingival enlargement: a case report..  SADJ : journal of the South African Dental Association = tydskrif van die Suid-Afrikaanse Tandheelkundige Vereniging,  67  ((7)): (344-347).  [PMID:23951790]
25. Hiroaki Shimizu,Takayuki Saitoh,Nahoko Hatsumi,Satoru Takada,Hiroshi Handa,Takahiro Jimbo,Toru Sakura,Shuichi Miyawaki,Yoshihisa Nojima.  (2013-09-24)  Prevalence of extramedullary relapses is higher after allogeneic stem cell transplantation than after chemotherapy in adult patients with acute myeloid leukemia..  Leukemia research,  37  ((11)): (1477-1481).  [PMID:24054717]
26. Marta Stojak,Lidia Mazur,Malgorzata Opydo-Chanek,Malgorzata Lukawska,Irena Oszczapowicz.  (2013-10-15)  In vitro induction of apoptosis and necrosis by new derivatives of daunorubicin..  Anticancer research,  33  ((10)): (4439-4443).  [PMID:24123013]
27. Haisheng Peng,Dan Du,Jinqiu Zhang.  (2013-12-07)  Liposomes modified with p-aminophenyl-α-D-mannopyranoside: a promising delivery system in targeting the brain..  Therapeutic delivery,  4  ((12)): (1475-1477).  [PMID:24304243]
28. Yi-Yang Chen,Cih-En Huang,Hui-Ju Chou,Pei-Shan Tsai,Chang-Hsien Lu,Miao-Fen Chen,Kuan-Der Lee,Ping-Tsung Chen,Jrhau Lung,Chih-Cheng Chen.  (2013-12-18)  Mutant DNMT3A clone evading chemotherapy and infiltrating central nervous system in a patient with molecularly good-risk acute myeloid leukemia..  Annals of hematology,  93  ((8)): (1441-1442).  [PMID:24337413]
29. Sarah A Buckley,Megan Othus,Vladimir Vainstein,Janis L Abkowitz,Elihu H Estey,Roland B Walter.  (2014-01-03)  Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes..  American journal of hematology,  89  ((4)): (423-428).  [PMID:24382796]
30. Steven E Coutre,Megan Othus,Bayard Powell,Cheryl L Willman,Wendy Stock,Elisabeth Paietta,Denise Levitan,Meir Wetzler,Eyal C Attar,Jessica K Altman,Steven D Gore,Tracy Maher,Kenneth J Kopecky,Martin S Tallman,Richard A Larson,Frederick R Appelbaum.  (2014-02-18)  Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy..  British journal of haematology,  165  ((4)): (497-503).  [PMID:24528179]
31. Yanyan Mei,Chao Gao,Kailing Wang,Lei Cui,Weijing Li,Xiaoxi Zhao,Feifei Liu,Minyuan Wu,Guoren Deng,Wei Ding,Hongti Jia,Zhigang Li.  (2014-04-12)  Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia..  Cancer science,  105  ((4)): (463-472).  [PMID:24720529]
32. Jakub Hofman,Beata Malcekova,Adam Skarka,Eva Novotna,Vladimir Wsol.  (2014-05-17)  Anthracycline resistance mediated by reductive metabolism in cancer cells: the role of aldo-keto reductase 1C3..  Toxicology and applied pharmacology,  278  ((3)): (238-248).  [PMID:24832494]
33. Jessica L Heath,Shelly E Burgett,Ana M Gaca,Ronald Jaffe,Daniel S Wechsler.  (2014-06-04)  Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy..  Pediatric blood & cancer,  61  ((10)): (1874-1876).  [PMID:24888336]
34. Petr Kosztyu,Romana Bukvova,Petr Dolezel,Petr Mlejnek.  (2014-06-24)  Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells..  Chemico-biological interactions,  219  (203-210).  [PMID:24954033]
35. Caroline Damico Candido,Michel Leandro Campos,Juliana Uruguay Correa Vidigal Assumpção,Kelly Chrystina Pestana,Elias Carvalho Padilha,Iracilda Zeppone Carlos,Rosângela Gonçalves Peccinini.  (2014-08-08)  Biocompatible microemulsion modifies the tissue distribution of doxorubicin..  Journal of pharmaceutical sciences,  103  ((10)): (3297-3301).  [PMID:25100266]
36. Hernan Carol,Mannie M Y Fan,Troy O Harasym,Ingrid Boehm,Lawrence D Mayer,Peter Houghton,Malcolm A Smith,Richard B Lock.  (2014-09-10)  Efficacy of CPX-351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program..  Pediatric blood & cancer,  62  ((1)): (65-71).  [PMID:25203866]
37. Jorge E Cortes,Stuart L Goldberg,Eric J Feldman,David A Rizzeri,Donna E Hogge,Melissa Larson,Arnaud Pigneux,Christian Recher,Gary Schiller,Krzysztof Warzocha,Hagop Kantarjian,Arthur C Louie,Jonathan E Kolitz.  (2014-09-17)  Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML..  Cancer,  121  ((2)): (234-242).  [PMID:25223583]
38. Takuya Suzuki,Masako Ichihara,Kenji Hyodo,Eiichi Yamamoto,Tatsuhiro Ishida,Hiroshi Kiwada,Hiroshi Kikuchi,Hiroshi Ishihara.  (2014-10-05)  Influence of dose and animal species on accelerated blood clearance of PEGylated liposomal doxorubicin..  International journal of pharmaceutics,  476  ((1-2)): (205-212).  [PMID:25280884]
39. Luca Maurillo,Francesco Buccisano,Alfonso Piciocchi,Maria Ilaria Del Principe,Chiara Sarlo,Ambra Di Veroli,Paola Panetta,Maria Irno-Consalvo,Daniela Nasso,Concetta Ditto,Marco Refrigeri,Gottardo De Angelis,Raffaella Cerretti,William Arcese,Giuseppe Sconocchia,Francesco Lo-Coco,Sergio Amadori,Adriano Venditti.  (2014-11-08)  Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia..  American journal of hematology,  90  ((2)): (125-131).  [PMID:25377359]
40. Tomasz Wojcik,Elzbieta Buczek,Katarzyna Majzner,Agnieszka Kolodziejczyk,Justyna Miszczyk,Patrycja Kaczara,Wojciech Kwiatek,Malgorzata Baranska,Marek Szymonski,Stefan Chlopicki.  (2014-12-23)  Comparative endothelial profiling of doxorubicin and daunorubicin in cultured endothelial cells..  Toxicology in vitro : an international journal published in association with BIBRA,  29  ((3)): (512-521).  [PMID:25529801]
41. Daniel C Ferguson,Qiuying Cheng,Javier G Blanco.  (2015-04-29)  Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218..  Drug metabolism and disposition: the biological fate of chemicals,  43  ((7)): (922-927).  [PMID:25918240]
42. Andrea R Beyer,Lauren VieBrock,Kyle G Rodino,Daniel P Miller,Brittney K Tegels,Richard T Marconi,Jason A Carlyon.  (2015-07-15)  Orientia tsutsugamushi Strain Ikeda Ankyrin Repeat-Containing Proteins Recruit SCF1 Ubiquitin Ligase Machinery via Poxvirus-Like F-Box Motifs..  Journal of bacteriology,  197  ((19)): (3097-3109).  [PMID:26170417]
43. Siyam M Ansar,Thilak Mudalige.  (2019-12-06)  Characterization of doxorubicin liposomal formulations for size-based distribution of drug and excipients using asymmetric-flow field-flow fractionation (AF4) and liquid chromatography-mass spectrometry (LC-MS)..  International journal of pharmaceutics,  574  (118906-118906).  [PMID:31805309]
44. Cristina Morales Torres,Mary Y Wu,Sebastijan Hobor,Elanor N Wainwright,Matthew J Martin,Harshil Patel,William Grey,Eva Grönroos,Steven Howell,Joana Carvalho,Ambrosius P Snijders,Michael Bustin,Dominique Bonnet,Paul D Smith,Charles Swanton,Michael Howell,Paola Scaffidi.  (2020-04-15)  Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis..  Nature communications,  11  ((1)): (1792-1792).  [PMID:32286289]
45. Mamta Amrute-Nayak,Gloria Pegoli,Tim Holler,Alfredo Jesus Lopez-Davila,Chiara Lanzuolo,Arnab Nayak.  (2020-12-12)  Chemotherapy triggers cachexia by deregulating synergetic function of histone-modifying enzymes..  Journal of cachexia, sarcopenia and muscle,  12  ((1)): (159-176).  [PMID:33305533]
46. Jay Chhablani,Alejandra Nieto,Huiyuan Hou,Elizabeth C Wu,William R Freeman,Michael J Sailor,Lingyun Cheng.  (2013-01-17)  Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system..  Investigative ophthalmology & visual science,  54  ((2)): (1268-1279).  [PMID:23322571]
47. Qian Ding,Ran Gu,Jiayi Liang,Xiangzhong Zhang,Yunxian Chen.  (2013-01-22)  PI-103 sensitizes acute myeloid leukemia stem cells to daunorubicin-induced cytotoxicity..  Medical oncology (Northwood, London, England),  30  ((1)): (395-395).  [PMID:23335068]
48. Ishrat Jabeen,Penpun Wetwitayaklung,Peter Chiba,Manuel Pastor,Gerhard F Ecker.  (2013-02-13)  2D- and 3D-QSAR studies of a series of benzopyranes and benzopyrano[3,4b][1,4]-oxazines as inhibitors of the multidrug transporter P-glycoprotein..  Journal of computer-aided molecular design,  27  ((2)): (161-171).  [PMID:23400406]
49. Anna Rommer,Birgit Steinmetz,Friederike Herbst,Hubert Hackl,Petra Heffeter,Daniela Heilos,Martin Filipits,Katarina Steinleitner,Shayda Hemmati,Irene Herbacek,Ilse Schwarzinger,Katharina Hartl,Pieter Rondou,Hanno Glimm,Kadin Karakaya,Alwin Krämer,Walter Berger,Rotraud Wieser.  (2013-03-05)  EVI1 inhibits apoptosis induced by antileukemic drugs via upregulation of CDKN1A/p21/WAF in human myeloid cells..  PloS one,  8  ((2)): (e56308-e56308).  [PMID:23457546]
50. Stephen H Petersdorf,Kenneth J Kopecky,Marilyn Slovak,Cheryl Willman,Thomas Nevill,Joseph Brandwein,Richard A Larson,Harry P Erba,Patrick J Stiff,Robert K Stuart,Roland B Walter,Martin S Tallman,Leif Stenke,Frederick R Appelbaum.  (2013-04-18)  A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia..  Blood,  121  ((24)): (4854-4860).  [PMID:23591789]
51. Jae-Ho Yoon,Byung-Sik Cho,Hee-Je Kim,Jung-Ho Kim,Seung-Hwan Shin,Seung-Ah Yahng,Sung-Eun Lee,Ki-Seong Eom,Yoo-Jin Kim,Seok Lee,Chang-Ki Min,Seok-Goo Cho,Dong-Wook Kim,Jong-Wook Lee,Woo-Sung Min,Chong-Won Park.  (2013-08-29)  Outcomes of elderly de novo acute myeloid leukemia treated by a risk-adapted approach based on age, comorbidity, and performance status..  American journal of hematology,  88  ((12)): (1074-1081).  [PMID:23983148]
52. Carlos E Vigil,Wei Tan,George Deeb,Sheila N Sait,Annemarie W Block,Petr Starostik,Elizabeth A Griffiths,James E Thompson,Jessica D Greene,Laurie A Ford,Eunice S Wang,Meir Wetzler.  (2013-09-10)  Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age..  Leukemia research,  37  ((11)): (1468-1471).  [PMID:24011826]
53. Robert S Nickel,Frank Keller,John Bergsagel,Todd Cooper,Marla Daves,Himalee Sabnis,Glen Lew.  (2013-12-21)  Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma..  Pediatric blood & cancer,  61  ((5)): (810-814).  [PMID:24357218]
54. Sylvain Pilorge,Sophie Rigaudeau,Florence Rabian,Clémentine Sarkozy,Anne L Taksin,Hassan Farhat,Fathia Merabet,Stéphanie Ghez,Victoria Raggueneau,Christine Terré,Isabelle Garcia,Aline Renneville,Claude Preudhomme,Sylvie Castaigne,Philippe Rousselot.  (2014-01-01)  Fractionated gemtuzumab ozogamicin and standard dose cytarabine produced prolonged second remissions in patients over the age of 55 years with acute myeloid leukemia in late first relapse..  American journal of hematology,  89  ((4)): (399-403).  [PMID:24375467]
55. Antonio R Lucena-Araujo,Haesook T Kim,Rafael H Jacomo,Raul A Melo,Rosane Bittencourt,Ricardo Pasquini,Katia Pagnano,Evandro M Fagundes,Maria de Lourdes Chauffaille,Carlos S Chiattone,Ana Silvia Lima,Guillermo Ruiz-Argüelles,Maria Soledad Undurraga,Lem Martinez,Hau C Kwaan,Robert Gallagher,Charlotte M Niemeyer,Stanley L Schrier,Martin S Tallman,David Grimwade,Arnold Ganser,Nancy Berliner,Raul C Ribeiro,Francesco Lo-Coco,Bob Löwenberg,Miguel A Sanz,Eduardo M Rego.  (2014-07-02)  Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study..  Annals of hematology,  93  ((12)): (2001-2010).  [PMID:24981688]
56. Enrico De Astis,Marino Clavio,Anna Maria Raiola,Anna Ghiso,Fabio Guolo,Paola Minetto,Federica Galaverna,Maurizio Miglino,Carmen Di Grazia,Filippo Ballerini,Carlo Marani,Giordana Pastori,Laura Mitscheunig,Fabio Cruciani,Davide Lovera,Riccardo Varaldo,Chiara Ghiggi,Roberto Massimo Lemoli,Andrea Bacigalupo,Marco Gobbi.  (2014-07-06)  Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia..  Annals of hematology,  93  ((12)): (2011-2018).  [PMID:24989345]
57. Jiezhou Pan, Haotian Liao, Guidong Gong, Yunxiang He, Qin Wang, Lang Qin, Yaoyao Zhang, Hirotaka Ejima, Blaise L. Tardy, Joseph J. Richardson, Jiaojiao Shang, Orlando J. Rojas, Yong Zeng, Junling Guo.  (2023)  Supramolecular nanoarchitectonics of phenolic-based nanofiller for controlled diffusion of versatile drugs in hydrogels.  JOURNAL OF CONTROLLED RELEASE,  360  (433).  [PMID:37422124]
58. Bo Fu, Can Tao, Nian Chen, Jie-Rou Lin, Ping Zhao.  (2021)  ZnO QD covalently coated, GSH/pH dual-responsive drug delivery system for chemotherapeutic/ionic synergistic therapy.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,  66  (102908).  [PMID:]
59. Zhifeng Xu, Peihong Deng, Junhua Li, Li Xu, Siping Tang.  (2017)  Molecularly imprinted fluorescent probe based on FRET for selective and sensitive detection of doxorubicin.  Materials Science and Engineering B-Advanced Functional Solid-State Materials,  218  (31).  [PMID:]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.